scholarly journals Does Exercise Have a Preventive Effect on Secondary Lymphedema in Breast Cancer Patients Following Local Treatment - A Systematic Review

Breast Care ◽  
2018 ◽  
Vol 13 (5) ◽  
pp. 380-385 ◽  
Author(s):  
Freerk T. Baumann ◽  
Alexandra Reike ◽  
Michael Hallek ◽  
Joachim Wiskemann ◽  
Vanessa Reimer
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Strength Training ◽  
Local Treatment ◽  
Exercise Group ◽  
Current Data ◽  
Cochrane Library ◽  
Breast Cancer Patients ◽  
Preventive Effect ◽  
Secondary Lymphedema

Background: Secondary lymphedema (SL) is a possible side effect of breast cancer treatment. Current data describe a positive influence of exercise on upper lymphedema. This systematic review evaluates studies examining a potential preventive effect of exercise on SL incidence. Methods: A systematic literature search of PubMed, LIVIVO, and the Cochrane Library was performed. Results: 8 randomized controlled trials were included in the review. 3 studies investigated the effect of strength training, and 5 the effect of combined exercise therapy. 5 studies included participants without lymphedema at study entry, and 3 studies included both patients with and without lymphedema. The partly significant results showed that progressive strength training as well as combined dynamic exercise therapies consisting of physiotherapy, physical therapy, and/or kinesiotherapy are safe and can prevent SL. Onset as well as diagnosis of lymphedema were significantly decreased in 5 studies in the exercise group. Conclusion: All 8 studies included indicate a potential preventive effect of exercise on SL; however, further research is needed.

scholarly journals Dance as treatment therapy in breast cancer patients – a systematic review

2017 ◽  
Vol 22 (4) ◽  
pp. 319-331 ◽  
Author(s):  
Leonessa Boing ◽  
Aline Dandara Rafael ◽  
Helena de Oliveira Braga ◽  
Alan de Jesus Pires De Moraes ◽  
Fabiana Flores Sperandio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Dance Therapy ◽  
Scientific Evidence ◽  
Well Being ◽  
Disease Stage ◽  
Cochrane Library ◽  
Breast Cancer Patients ◽  
Psychological Benefits ◽  
Classical Ballet

This systematic review aimed to identify and analyse articles which investigated the influence of dance as adjuvant therapy in breast cancer. The selected databases were PsycInfo, PubMed, The Cochrane Library, ScienceDirect and the Virtual Health Library (VHL). The following descriptors were considered for the selection of articles: [dance therapy] OR [movement therapy] OR [complementary therapies] AND [breast cancer] OR [cancer neoplasms] OR [breast tumor] OR [breast carcinoma] present in the titles or abstracts of the articles. The quality of the data was evaluated by means of the methodological criteria proposed by Downs and Black. Eleven articles were found. The approach followed in methodologies were dance therapy movement, Greek dance, Sacred dance, ballroom dance, classical ballet and jazz. Favorable results were found for self-image, femininity, mood, self-esteem, physical well-being, perceived stress, pain, consciousness, depression, couples trust, anxiety and fear. It was observed better range of motion and strength in upper limp, and also improvement in functional capacity. The authors pointed dance as an effective alternative adjuvant treatment in breast cancer. Dance promotes psychological benefits in women in breast cancer, as well as improvements in upper limbs. Future studies are recommended with best scientific evidence, in order to investigate interventions with dance during other treatment and disease stage and with other forms of dance.

scholarly journals The Risk of Psychological Stress on Cancer Recurrence: A Systematic Review

Cancers ◽  
2021 ◽  
Vol 13 (22) ◽  
pp. 5816
Author(s):  
Hyeon-Muk Oh ◽  
Chang-Gue Son
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Cohort Studies ◽  
Cancer Patients ◽  
Psychological Stress ◽  
Cancer Recurrence ◽  
Current Evidence ◽  
Cochrane Library ◽  
Breast Cancer Patients ◽  
Data Points

Cancer recurrence is a significant clinical issue in cancer treatment. Psychological stress has been known to contribute to the incidence and progression of cancer; however, its effect on cancer recurrence remains inconclusive. We conducted a systematic review to examine the current evidence from the Medline (PubMed), Embase and Cochrane Library up to May 2021. Among 35 relevant articles, a total of 6 studies (10 data points) were finally selected, which enrolled 26,329 patients (26,219 breast cancer patients except hepatocellular carcinoma patients in 1 study), 4 cohort studies (8 data points) and 2 RCTs (2 data points). Among the 8 data points in cohort studies, four psychological stress-related factors (two ‘anxiety’, one ‘depression’, and one ‘hostility’) were shown to be moderately related with the risk for cancer recurrence, while ‘loss of partner’ resulted in opposite outcomes. The ‘emotional‘ and ‘mental’ health factors showed conflicting results, and an RCT-derived meta-analysis proved the positive efficiency of psychotherapies in reducing the cancer recurrence risk among breast cancer patients (HR = 0.52; 95% CI 0.33–0.84). Despite the limitations, this study produces comprehensive information about the effect of psychological stress on cancer recurrence and provides reference data to clinicians and scientists for further studies.

scholarly journals What is the Current Effectiveness of Olaparib for Breast Cancer Patients with a BRCA Mutation? A Systematic Review

2019 ◽  
Vol 13 (1) ◽  
pp. 39-59
Author(s):  
Polly Marsh ◽  
Graham R Williamson
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Clinical Trials ◽  
Cancer Patients ◽  
Brca Mutation ◽  
Meta Analysis ◽  
Grey Literature ◽  
Gene Mutations ◽  
Cochrane Library ◽  
Breast Cancer Patients

Background:The Poly (ADP-ribose) polymerase inhibitor olaparib, acts against cancer cells in people with breast cancer pre-disposition gene mutations (BRCAm). Despite US and EU approval as a therapy for ovarian cancer patients with BRCAm, but research into olaparib therapy for breast cancer patients with BRCAm is in its infancy.Objective:As no systematic review has yet been undertaken to synthesise clinical trials looking at olaparib as a therapy for breast cancer patients with BRCAm, this systematic review aims to establish the current effectiveness of olaparib as a treatment for these patients.Methods:CINAHL, MEDLINE, Royal College of Nursing, Cochrane Library, Joanna Briggs Institute, Centre for Reviews and Dissemination, Internurse, Embase, Google Scholar and PubMed databases were searched, supplemented by a grey literature search, hand searching and cross-referencing. Authors independently reviewed and graded the studies also using Kmetet al. scoring system.Results:One long-term case study and six clinical trials were included. Heterogeneity prevented statistical meta-analysis, meaning only narrative synthesis was possible. The overall clinical benefit of olaparib appears to be greater and longer lived in BRCAm carriers compared to BRCAwt, and also when compared to standard chemotherapy treatments.Conclusion:Implications for nursing: nurses working in this field should be aware that the most compelling results were found in the subset of patients who harbour a BRCA mutation, meaning that olaparib should be regarded as a clinically effective potential therapy for these patients. Larger, longer-term trials including comparator arms are required to demonstrate benefits including overall survival, adverse effects and quality of life.

scholarly journals Age at Diagnosis of Breast Cancer in Iran: A Systematic Review and Meta-Analysis

2021 ◽  
Author(s):  
Mahasti Alizadeh ◽  
Morteza Ghojazadeh ◽  
Reza Piri ◽  
Mohammad Mirza-Aghazadeh-Attari ◽  
Sahar Mohammadi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Age At Diagnosis ◽  
Cochrane Library ◽  
Breast Cancer Patients ◽  
Female Patients ◽  
Wide Range ◽  
The Mean

Background: Breast cancer is responsible for up to 25% of all cancers in Iran. The age at diagnosis of Iranian breast cancer patients starts a decade earlier than most of developed countries. This study aimed to evaluate the mean age at diagnosis of Iranian breast cancer patients. Methods: In this systematic review and meta-analysis, the mean age at diagnosis of Iranian breast cancer patients and its pattern between 2008 and 2017, were evaluated. All papers with age at diagnosis of histopathological verified breast cancer patients were considered eligible to enter to the analysis. We used databases including Medline/PubMed, Scopus, Embase, Cochrane Library, Iranmedex and SID for the search process. The meta-analysis was performed only on studies with separate data for female patients, using random-effects model, Mantel and Haenszel method and the Comprehensive Meta-analysis software. Results: Finally, 92 studies with 19,784 patients (both-genders) were included. The mean age at diagnosis had increased from 47.93 (2008) to 49.91 (2016) years. The meta-analysis was done on 78 studies containing of 15,071 female patients and the mean age at diagnosis was 46.76±1.19. There was a wide range of age at diagnosis within different provinces. The mean age at Hamadan and Khuzestan provinces were the lowest and highest, respectively (42.48±7.96 vs. 51.00±11.47). The heterogeneity of studies was statistically significant (I2=99.744). Conclusion: Mean age at diagnosis of Iranian women with breast cancer was 46.76±1.19. There was an increasing pattern in mean age of diagnosis at breast cancer patients within the past 10 years.

Effectiveness of Supportive-Expressive Group Therapy in Women with Breast Cancer: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 44 (5) ◽  
pp. 252-260
Author(s):  
Jiawei Lai ◽  
Huijuan Song ◽  
Ying Ren ◽  
Shuang Li ◽  
Feng Xiao
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Group Therapy ◽  
Meta Analysis ◽  
Poor Quality ◽  
Convincing Evidence ◽  
Cochrane Library ◽  
Breast Cancer Patients ◽  
Impact On Survival ◽  
Meta Analyses

<b><i>Introduction:</i></b> Breast cancer is the most frequently diagnosed cancer among women and ranks second in terms of global incidence. Depression, anxiety, and poor quality of life (QoL) are prevalent in women with breast cancer. Supportive-expressive group therapy (SEGT) can potentially benefit these patients. <b><i>Objective:</i></b> This systematic review and meta-analysis evaluated the effectiveness of SEGT for women with breast cancer, by focusing on survival, QoL, anxiety, and depression as outcomes. <b><i>Methods:</i></b> The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were adopted. The databases PubMed, Web of Science, Cochrane Library, Embase, CINHAL, and PsycInfo in English, and Sinomed, CNKI, CQVIP, and Wanfang in Chinese, were searched from inception up to May 2020 for relevant full-text articles using “SEGT,” “breast cancer,” and related terms as keywords. Randomized controlled trials (RCTs) comparing SEGT with baseline conditions of patients with breast cancer were included in the analysis. <b><i>Results:</i></b> Ten studies with a total of 2,879 subjects were analyzed. Overall group differences were found for survival (hazard ratio [HR] 0.82, 95% confidence interval [CI] 0.72–0.94; <i>p</i> = 0.004), short-term QoL (mean difference [MD] 8.02, 95% CI 4.85–11.20; <i>p</i> &#x3c; 0.00001), long-term QoL (MD 11.30, 95% CI 6.75–15.84; <i>p</i> &#x3c; 0.00001), Profile of Mood States score (POMS) score (MD –0.43, 95% CI –0.72 to –0.13; <i>p</i> = 0.005), anxiety (standardized MD [SMD] –0.30, 95% CI –0.49 to –0.10; <i>p</i> = 0.003), and depression (SMD –0.47, 95% CI –0.66 to –0.29; <i>p</i> &#x3c; 0.00001). <b><i>Conclusions:</i></b> SEGT is effective in improving QoL and psychosocial status in breast cancer patients, but there is no convincing evidence that it has an impact on survival.

scholarly journals Diagnostic value of serum HER2 levels in breast cancer: a systematic review and meta-analysis

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Amir Shamshirian ◽  
Amir Reza Aref ◽  
George W. Yip ◽  
Majid Ebrahimi Warkiani ◽  
Keyvan Heydari ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Cancer Patients ◽  
Likelihood Ratio ◽  
Predictive Value ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Breast Cancer Patients ◽  
Diagnostic Screening ◽  
Her 2

Abstract Background Measurement of serum human epidermal growth factor receptor-2 (HER-2/neu) levels might play an essential role as a diagnostic/screening marker for the early selection of therapeutic approaches and predict prognosis in breast cancer patients. We aimed to undertake a systematic review and meta-analysis focusing on the diagnostic/screening value of serum HER-2 levels in comparison to routine methods. Methods We performed a systematic search via PubMed, Scopus, Cochrane-Library, and Web of Science databases for human diagnostic studies reporting the levels of serum HER-2 in breast cancer patients, which was confirmed using the histopathological examination. Meta-analyses were carried out for sensitivity, specificity, accuracy, area under the ROC curve (AUC), positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR), and negative likelihood ratio (NLR). Results Fourteen studies entered into this investigation. The meta-analysis indicated the low sensitivity for serum HER2 levels (Sensitivity: 53.05, 95%CI 40.82–65.28), but reasonable specificity of 79.27 (95%CI 73.02–85.51), accuracy of 72.06 (95%CI 67.04–77.08) and AUC of 0.79 (95%CI 0.66–0.92). We also found a significant differences for PPV (PPV: 56.18, 95%CI 44.16–68.20), NPV (NPV: 76.93, 95%CI 69.56–84.31), PLR (PLR: 2.10, 95%CI 1.69–2.50) and NLR (NLR: 0.58, 95%CI 0.44–0.71). Conclusion Our findings revealed that although serum HER-2 levels showed low se nsitivity for breast cancer diagnosis, its specificity, accuracy and AUC were reasonable. Hence, it seems that the measurement of serum HER-2 levels can play a significant role as a verification test for initial negative screening test results, especially in low-income regions due to its cost-effectiveness and ease of implementation.

scholarly journals Prevalence of retinopathy in prediabetes: protocol for a systematic review and meta-analysis

BMJ Open ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. e040997
Author(s):  
Varo Kirthi ◽  
Paul Nderitu ◽  
Uazman Alam ◽  
Jennifer Evans ◽  
Sarah Nevitt ◽  
...  
Keyword(s):  
Systematic Review ◽  
Diabetic Retinopathy ◽  
Data Extraction ◽  
Meta Analysis ◽  
International Diabetes Federation ◽  
Current Data ◽  
Risk Of Bias ◽  
Fundus Photography ◽  
Primary Data ◽  
Cochrane Library

IntroductionThere is growing evidence of a higher than expected prevalence of retinopathy in prediabetes. This paper presents the protocol of a systematic review and meta-analysis of retinopathy in prediabetes. The aim of the review is to estimate the prevalence of retinopathy in prediabetes and to summarise the current data.Methods and analysisThis protocol is developed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) guidelines. A comprehensive electronic bibliographic search will be conducted in MEDLINE, EMBASE, Web of Science, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Google Scholar and the Cochrane Library. Eligible studies will report prevalence data for retinopathy on fundus photography in adults with prediabetes. No time restrictions will be placed on the date of publication. Screening for eligible studies and data extraction will be conducted by two reviewers independently, using predefined inclusion criteria and prepiloted data extraction forms. Disagreements between the reviewers will be resolved by discussion, and if required, a third (senior) reviewer will arbitrate.The primary outcome is the prevalence of any standard features of diabetic retinopathy (DR) on fundus photography, as per International Clinical Diabetic Retinopathy Severity Scale (ICDRSS) classification. Secondary outcomes are the prevalence of (1) any retinal microvascular abnormalities on fundus photography that are not standard features of DR as per ICDRSS classification and (2) any macular microvascular abnormalities on fundus photography, including but not limited to the presence of macular exudates, microaneurysms and haemorrhages. Risk of bias for included studies will be assessed using a validated risk of bias tool for prevalence studies. Pooled estimates for the prespecified outcomes of interest will be calculated using random effects meta-analytic techniques. Heterogeneity will be assessed using the I2 statistic.Ethics and disseminationEthical approval is not required as this is a protocol for a systematic review and no primary data are to be collected. Findings will be disseminated through peer-reviewed publications and presentations at national and international meetings including Diabetes UK, European Association for the Study of Diabetes, American Diabetes Association and International Diabetes Federation conferences.PROSPERO registration numberCRD42020184820.

Sign in / Sign up

Export Citation Format

Share Document